Feed BNTX
BN

BioNTech

BNTX · NASDAQ

$96.73 -0.04% (-$0.04)
1M +5.60%
Market Cap 21.0B €
P/E Ratio -
Div. Yield -
ROE 9.13%

Bulios Fair Price

$113.59

17.4% upside

Preț actual

$96.73

Subevaluat Valoare justă Supraevaluat

Potrivit Bulios Fair Price, acțiunile BNTX sunt în prezent subevaluate față de prețul lor de piață. Cum funcționează?

Bulios Fair Price este o estimare a valorii corecte a unei acțiuni din modelul de evaluare Bulios. Este un punct de plecare pentru propria analiză, nu o recomandare de investiții. Cum funcționează?

Piotroski F-Score Weak
2/9
Valuation
37 /100
Fair
P/FCF 40.43x
P/S 7.93x
P/B 1.18x
Growth
3 /100
Declining
Book val. growth 1.42%
Rev. growth 45.80%
FCF growth 72.67%
Profitability
50 /100
Moderate
Op. margin 71.79%
Gross margin 70.82%
FCF margin 19.61%
Quality
2 /100
Poor
ROA 8.32%
ROIC 10.64%
Asset turnover 0.13x
Debt
69 /100
Low
Int. coverage -86.04x
Debt/Equity 0.02x
Current ratio 7.85x
Stability
24 /100
Unstable
EPS volatility 57.07%
Beta 1.29x
Profitable years 0

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre BNTX
Online

Despre companie

BioNTech SE is a German biotechnology company focused on the research and development of innovative drugs and therapeutic approaches. The company is well-known for its groundbreaking research and development of mRNA (messenger RNA) technology, which serves as the basis for drug and vaccine development. BioNTech collaborates with pharmaceutical and research partners worldwide and focuses on addressing serious diseases such as cancer, infectious diseases, and others. It gained significant recognition through its collaboration with Pfizer on the development and distribution of the COVID-19 vaccine, which became the first mRNA vaccine approved for emergency use. BioNTech SE adheres to high standards of scientific research and innovation and emphasizes the potential to change the way diseases are treated and prevented. Investing in BioNTech SE (BNTX) shares may be an interesting choice for investors who follow the biotechnology sector and seek investment opportunities in an innovative company with promising medical technologies.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Ugur Sahin

Employees

7,807

Headquarters

Mainz

Evenimente viitoare

03 NOV.

Earnings

Upcoming earnings report

50d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.